Everest Medicines has entered into a non-binding letter of intent to acquire the entire equity interest in Haisco Pharmaceutical (Singapore) Pte. Ltd. from its parent company, Haisco Pharmaceutical (Asia) Ltd. The potential acquisition aims to enrich Everest's existing product pipeline, expand its business scale in the Asia-Pacific region and accelerate the build-out of a commercialisation platform for innovative drugs across the region. As part of the agreement, Everest will pay its China compatriot a refundable deposit of RMB 200 million (USD 27.8 million), which may be applied towards the future purchase consideration.

Haisco Pharmaceutical (Singapore) focuses on the commercialisation of prescription drugs for chronic and critical diseases, particularly in cardiovascular and metabolic areas. It holds marketing authorisations, trademarks and broad commercialisation rights for 14 chronic disease products across multiple APAC markets. The deal aligns with Everest's strategic focus on chronic diseases, such as cardiovascular, renal and metabolic conditions. The companies have agreed to a six-month exclusivity period to conduct due diligence and negotiate definitive terms.

PharmCube's NextBiopharm® database shows that four companies have previously shown interest in Haisco's assets through licensing deals. Click here to request a free trial for NextBiopharm®.